EN FR ABOUT KURMA TEAM OUR FUNDS PORTFOLIO NEWS VIDEOS CONTACT MAJOR PLAYER IN THE FUNDING OF HEALTHCARE AND BIOTECHNOLOGY IN EUROPE We invest at various stages of maturity, from company creation to capital expansion Crédit photo : Institut Pasteur 1. OUR VISION WE HAVE HIGH STANDARDS We have built a strong network of partners with the best European academic research players, to transform their disruptive scientific discoveries into cutting-edge medicines or medical devices to diagnose and treat patients with severe diseases with high unmet medical need. WE BUILD COMPANIES Our ambition is to work with leading European research centers to build the healthcare industry of tomorrow. In that perspective, we have developed a unique approach. We work closely with the research teams early on to define a plan to validate their discoveries and bring together the best healthcare industry experts and later the most experienced entrepreneurs to create high-tech companies. We provide capital/funding to the companies we have founded with our funds and invite other investors to join us. This new and distinctive approach makes us stand out from most players in the world of healthcare investment and has enabled us to build more than 10 companies over the past 10 years. We are also involved in early stage companies that have already been created, but always by supporting their development by providing our expertise and network. We have thus contributed to the financing of more than 40 companies, many of which have become recognized leaders in their respective sectors. WE HAVE IMPACT Because of our business, we are players in the world of healthcare and as such are committed to making our contribution to sustainable development. We adhere to the ESG practices we have established 2. OUR STORY 2009 Co-creation of Kurma Partners by Thierry Laugel 2009 Closing of Kurma Biofund I 2010 Rémi Droller joins Kurma Partners 2012 Sylvain Cascarino joins Kurma Partners 2013 Closing of Kurma Biofund II 2013 Vanessa Malier joins Kurma Partners 2015 Closing of Kurma Diagnostics 1 2015 Alain Horvais and Philippe Peltier join Kurma Partners 2016 Kurma Partners majority owned by its partners Partners acquired majority shareholding of the management company 2017 Delegate management of Paris Saclay Seed Fund 2018 First closing of Kurma Biofund III 2019 Peter Neubeck joins Kurma Partners 2019 Opening of the office in Germany 2020 Final closing of Kurma Biofund III 2020 First closing of Kurma Diagnostics II 2020 Benjamin Belot joins Kurma Partners 3. KEY DATA 25 companies financed since 2009 13 companies founded since 2009 251 million € under management 427 employees in companies financed 4. OUR PARTNERS Kurma has created a solid network of partners to transform their most disruptive scientific discoveries into cutting-edge drugs or medical devices for the diagnosis and treatment of patients with severe diseases with high unmet medical need. 5. OUR PROACTIVE ESG APPROACH Download our ESG Charter Download our CSR Policy ABOUT KURMA TEAM OUR FUNDS PORTFOLIO NEWS VIDEOS CONTACT FOLLOW US CONTACT@KURMAPARTNERS.COM Tél: +33 (0)1 84 86 08 61 24, rue Royale 75008 Paris France © COPYRIGHT KURMA PARTNERS. LEGAL NOTICE REGULATORY INFORMATION PRIVATE POLICY DESIGN : AGENCE K2